AI Engines For more Details: Perplexity Kagi Labs You
Antipsychotic Effects: Aripiprazole is classified as an atypical antipsychotic medication. It works by helping to restore the balance of certain natural chemicals in the brain (neurotransmitters) that are imbalanced in patients with schizophrenia and bipolar disorder. By doing so, it helps to reduce symptoms such as hallucinations, delusions, and disorganized thinking associated with these conditions.
Mood Stabilizing Effects: In addition to its antipsychotic properties, aripiprazole also has mood-stabilizing effects. It can help stabilize mood fluctuations in patients with bipolar disorder, preventing episodes of mania and depression.
Adjunctive Treatment: Aripiprazole may be used as an adjunctive treatment alongside other medications to enhance their effectiveness in managing symptoms of mental disorders.
Oral and Injectable Formulations: Aripiprazole is available in both oral formulations (tablets, oral solution) and long-acting injectable formulations (e.g., Abilify Maintena, Aristada). Long-acting injectable formulations are administered less frequently (e.g., once monthly) and may be preferred for patients who have difficulty adhering to a daily oral medication regimen.
Side Effects: Like all medications, aripiprazole can cause side effects. Common side effects may include nausea, vomiting, constipation, headache, dizziness, drowsiness, and weight gain. These side effects are typically mild and transient, but some patients may experience more severe side effects.
Extrapyramidal Symptoms (EPS): Aripiprazole may cause extrapyramidal symptoms such as tremors, muscle stiffness, and involuntary movements (dyskinesias). These side effects are more common with typical antipsychotic medications but can occur with atypical antipsychotics like aripiprazole as well.
Metabolic Effects: Aripiprazole may lead to metabolic changes such as weight gain, increased blood sugar levels, and lipid abnormalities. Patients taking aripiprazole should be monitored regularly for changes in weight, blood glucose, and lipid levels.
Neurological Effects: In rare cases, aripiprazole may increase the risk of neuroleptic malignant syndrome (NMS), a serious neurological condition characterized by fever, muscle rigidity, altered mental status, and autonomic dysfunction. Patients should seek immediate medical attention if they experience symptoms suggestive of NMS.
Cardiovascular Effects: Aripiprazole may prolong the QT interval on electrocardiogram (ECG), which could potentially lead to cardiac arrhythmias. Patients with pre-existing cardiac conditions or those taking other medications that prolong the QT interval should use aripiprazole with caution.
Suicidal Thoughts: Like other antidepressant medications, aripiprazole may increase the risk of suicidal thoughts and behaviors, particularly in children, adolescents, and young adults. Patients should be closely monitored for signs of worsening depression or suicidal ideation, especially when starting or changing the dose of aripiprazole.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| Acne | 0.6 | 0.6 | |
| ADHD | 1.6 | 0.3 | 4.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 1.3 | 0 | 0 |
| Allergies | 3.1 | 1.6 | 0.94 |
| Allergy to milk products | 0.7 | 0.7 | 0 |
| Alopecia (Hair Loss) | 1.2 | 1.2 | |
| Alzheimer's disease | 3 | 3.5 | -0.17 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.2 | 0.6 | 2.67 |
| Ankylosing spondylitis | 2.1 | 0.3 | 6 |
| Anorexia Nervosa | 0.4 | 2 | -4 |
| Antiphospholipid syndrome (APS) | 0.7 | 0.7 | |
| Asthma | 2.3 | 0.9 | 1.56 |
| Atherosclerosis | 0.9 | 2.5 | -1.78 |
| Atrial fibrillation | 2.5 | 1.9 | 0.32 |
| Autism | 5 | 5.3 | -0.06 |
| Autoimmune Disease | 0.5 | -0.5 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0 | 0 | |
| Bipolar Disorder | 0.7 | 0.8 | -0.14 |
| Brain Trauma | 0.8 | -0.8 | |
| Breast Cancer | 0.3 | 0.3 | |
| Cancer (General) | 0.3 | 0.1 | 2 |
| Carcinoma | 1.6 | 1.6 | 0 |
| Celiac Disease | 2.2 | 1.6 | 0.38 |
| Cerebral Palsy | 0.3 | 0.8 | -1.67 |
| Chronic Fatigue Syndrome | 1 | 5.1 | -4.1 |
| Chronic Kidney Disease | 1.5 | 1.5 | 0 |
| Chronic Lyme | 0.2 | 0.8 | -3 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.8 | -1.67 |
| Chronic Urticaria (Hives) | 1.3 | -1.3 | |
| Coagulation / Micro clot triggering bacteria | 0.4 | 0.5 | -0.25 |
| Cognitive Function | 1.8 | 0.8 | 1.25 |
| Colorectal Cancer | 4.6 | 1.4 | 2.29 |
| Constipation | 0.7 | 0.5 | 0.4 |
| Coronary artery disease | 0.3 | 2.6 | -7.67 |
| COVID-19 | 2.8 | 5.7 | -1.04 |
| Crohn's Disease | 4.2 | 3.7 | 0.14 |
| Cushing's Syndrome (hypercortisolism) | 0.7 | -0.7 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 1.5 | 0.8 | 0.88 |
| Depression | 5.4 | 5.6 | -0.04 |
| Eczema | 0 | 1.2 | 0 |
| Endometriosis | 1.6 | 1.1 | 0.45 |
| Epilepsy | 0.9 | 1.4 | -0.56 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 2.2 | 2.6 | -0.18 |
| Functional constipation / chronic idiopathic constipation | 2.9 | 2.8 | 0.04 |
| gallstone disease (gsd) | 1.6 | 0.6 | 1.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1 | 1 | |
| Generalized anxiety disorder | 0.6 | 1.2 | -1 |
| Gout | 0.3 | 0.3 | 0 |
| Graves' disease | 0.7 | 1.7 | -1.43 |
| Gulf War Syndrome | 0.3 | 0.8 | -1.67 |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 2 | 0.3 | 5.67 |
| Heart Failure | 1.4 | 1.6 | -0.14 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.1 | 2 |
| hyperglycemia | 0.6 | 0.8 | -0.33 |
| Hyperlipidemia (High Blood Fats) | 0 | 0 | |
| hypertension (High Blood Pressure | 2 | 2.1 | -0.05 |
| Hypothyroidism | 0.3 | 0.3 | 0 |
| Hypoxia | 1.3 | 0.6 | 1.17 |
| IgA nephropathy (IgAN) | 0.7 | 1.3 | -0.86 |
| Inflammatory Bowel Disease | 2 | 4.8 | -1.4 |
| Insomnia | 1.2 | 1.2 | 0 |
| Intelligence | 0.7 | 0.6 | 0.17 |
| Intracranial aneurysms | 0.7 | 0.3 | 1.33 |
| Irritable Bowel Syndrome | 2.2 | 2.1 | 0.05 |
| ischemic stroke | 0.8 | 1.1 | -0.38 |
| Liver Cirrhosis | 3.3 | 2.4 | 0.38 |
| Long COVID | 3 | 2.8 | 0.07 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.7 | -0.7 | |
| Mast Cell Issues / mastitis | 0.3 | -0.3 | |
| ME/CFS with IBS | 0.6 | 1.5 | -1.5 |
| ME/CFS without IBS | 0 | 2.1 | 0 |
| Menopause | 0.6 | -0.6 | |
| Metabolic Syndrome | 3.1 | 3.6 | -0.16 |
| Mood Disorders | 4.5 | 3.8 | 0.18 |
| multiple chemical sensitivity [MCS] | 0 | 0 | |
| Multiple Sclerosis | 1.5 | 4.6 | -2.07 |
| Multiple system atrophy (MSA) | 0.1 | 0.1 | |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 1.9 | -1.9 | |
| Neuropathy (all types) | 0 | 1.9 | 0 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.3 | 2.1 | 0.1 |
| NonCeliac Gluten Sensitivity | 0.4 | 0.3 | 0.33 |
| Obesity | 5.6 | 3.9 | 0.44 |
| obsessive-compulsive disorder | 2 | 2.4 | -0.2 |
| Osteoarthritis | 0.4 | 0.3 | 0.33 |
| Osteoporosis | 0.8 | 0.9 | -0.13 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 3.4 | 4.5 | -0.32 |
| Polycystic ovary syndrome | 3.8 | 1.2 | 2.17 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.6 | 0.1 | 5 |
| Primary sclerosing cholangitis | 0.7 | 1.4 | -1 |
| Psoriasis | 1.2 | 3.4 | -1.83 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.4 | 3.2 | 0.06 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 1.5 | 1.6 | -0.07 |
| scoliosis | 0.3 | 0.3 | |
| Sjögren syndrome | 1.3 | 1.7 | -0.31 |
| Sleep Apnea | 0.9 | 1.1 | -0.22 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 1.9 | 1.6 | 0.19 |
| Systemic Lupus Erythematosus | 1.9 | 0.8 | 1.37 |
| Tic Disorder | 0.7 | 1.2 | -0.71 |
| Tourette syndrome | 0.6 | 0.3 | 1 |
| Type 1 Diabetes | 2.8 | 1.8 | 0.56 |
| Type 2 Diabetes | 4.7 | 3.4 | 0.38 |
| Ulcerative colitis | 2.3 | 4.5 | -0.96 |
| Unhealthy Ageing | 3 | 2.2 | 0.36 |
| Vitiligo | 1.3 | 1.1 | 0.18 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
